<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00614965</url>
  </required_header>
  <id_info>
    <org_study_id>CT/06.16</org_study_id>
    <nct_id>NCT00614965</nct_id>
  </id_info>
  <brief_title>Irinotecan Plus Cisplatin vs Pemetrexed Plus Cisplatin as 2nd Line in NSCLC Stage IIIB/IV</brief_title>
  <official_title>A Multicenter Randomized Phase II Study of the Combination of Irinotecan/Cisplatin Versus Pemetrexed/Cisplatin as Second-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic Oncology Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital of Crete</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hellenic Oncology Research Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will compare the efficacy of irinotecan/cisplatin and pemetrexed/cisplatin in the
      second-line treatment of patients with stage IIIB/IV NSCLC
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-platinum-based doublets including the newer drugs can be used instead of platinum-based
      regimens in the first line treatment of patients with advanced NSCLC. Docetaxel or pemetrexed
      have been proven effective as second-line treatment of patients with NSCLC. In a study
      conducted by our group the combination of irinotecan/cisplatin demonstrated higher response
      rates over cisplatin monotherapy in patients progressing after first-line
      docetaxel/gemcitabine. Moreover, pemetrexed has been combined with the platinums (ie,
      cisplatin, carboplatin, and oxaliplatin) in NSCLC to yield clinical activity similar to that
      of other platinum-based doublets. The efficacy of different platinum-based combinations in
      patients pretreated with non-platinum based first-line chemotherapy is not known.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Objective responses confirmed by CT or MRI (on 3rd and 6th cycle)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Tumor Progression</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile between the two treatment arms</measure>
    <time_frame>Toxicity assessment on each chemotherapy cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>Assessment every two cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan at the dose of 110 mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles</description>
    <arm_group_label>1</arm_group_label>
    <other_name>CPT-11</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin at the dose of 80 mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>CDDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pemetrexed at the dose of 500mg/m2 IV every 3 weeks for 6 consecutive cycles</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Alimta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed NSCLC

          -  Age 18 -75 years

          -  Performance status (WHO) &lt;2

          -  Patients progressing after first-line docetaxel/gemcitabine treatment

          -  Adequate bone marrow (absolute neutrophil count &gt;1000/mm3, platelet count &gt;100000/mm3,
             hemoglobin &gt; 9 gr/ mm3)

          -  Adequate liver (bilirubin &lt;1.5 times upper limit of normal), renal (Creatinine
             clearance &gt; 50mg/min) and cardiac (LVEF &gt;50%) function

          -  Presence of measurable disease (according to RESIST criteria)

          -  Informed consent

        Exclusion Criteria:

          -  Psychiatric illness or social situation that would preclude study compliance'

          -  Other concurrent uncontrolled illness.

          -  Other invasive malignancy within the past 5 years except nonmelanoma skin cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sofia Aggelaki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Crete, Dep of Medical Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Air Forces Military Hospital, Dep of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IASO&quot; General Hospital of Athens, 1st Dep of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2008</study_first_submitted>
  <study_first_submitted_qc>February 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2008</study_first_posted>
  <last_update_submitted>May 20, 2011</last_update_submitted>
  <last_update_submitted_qc>May 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>S.Aggelaki</name_title>
    <organization>Hellenic Oncology Research Group</organization>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>second-line chemotherapy</keyword>
  <keyword>irinotecan</keyword>
  <keyword>pemetrexed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

